Kyverna Therapeutics (KYTX) Assets Average (2024 - 2026)
Kyverna Therapeutics posted quarterly Assets Average of $275.4 million for Q1 2026, down 2.56% year-on-year from $282.6 million in Q1 2025, and up 14.53% on a QoQ basis from $240.5 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 3 years of Assets Average data on file, last reported at $275.4 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 2.56% year-over-year to $275.4 million; the trailing twelve-month figure through Mar 2026 stood at $275.4 million (down 2.56% YoY), and the FY2025 full-year result was $299.2 million, up 57.56% from the prior year.
- Assets Average for Q1 2026 stood at $275.4 million, up from $240.5 million in the prior quarter.
- Across five years, Assets Average topped out at $376.6 million in Q2 2024 and bottomed at $206.8 million in Q3 2025.
- The 3-year median for Assets Average is $275.4 million (2026), against an average of $281.2 million.
- Peak annual rise in Assets Average reached 21.52% in 2025, while the deepest fall reached 41.1% in 2025.
- A 3-year view of Assets Average shows it stood at $321.9 million in 2024, then declined by 25.29% to $240.5 million in 2025, then climbed by 14.53% to $275.4 million in 2026.
- The last three Assets Average figures came in at $275.4 million (Q1 2026), $240.5 million (Q4 2025), and $206.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | 275.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 275.43 Mn |
| Dec 31, 2025 | 240.49 Mn |
| Sep 30, 2025 | 206.83 Mn |
| Jun 30, 2025 | 243.58 Mn |
| Mar 31, 2025 | 282.65 Mn |
| Dec 31, 2024 | 321.92 Mn |
| Sep 30, 2024 | 351.16 Mn |
| Jun 30, 2024 | 376.55 Mn |
| Mar 31, 2024 | 232.59 Mn |